Pharmaresearch

Beta

KRX Filings & Disclosures 2026

Risk Factors

• • KRW 9.72B pre-tax profit sensitivity to 10% won appreciation/depreciation against foreign currencies at fiscal year-end 2025
• • KRW 722.5B equity and net cash position with KRW 290.1B negative net borrowings at FY2025-end

Management Discussion & Analysis

• • Revenue KRW 536.3B (+53% YoY), Operating Profit KRW 214.4B (+70%), Net Income KRW 168.3B (+89%) in FY2025
• • Export segment growth driven by expanded distribution and brand recognition in China, Japan, Southeast Asia, and North America

Business Overview

• • Revenue mix FY2025: medical devices 58.6%, cosmetics 24.6%, pharmaceutical products 15.4%, others 1.4%
• • Domestic launch of botulinum toxin product "Rientox 100 units" in April 2025 after Feb 1, 2024 approval

What are the latest Pharmaresearch DART filings in 2026?

Pharmaresearch (KRX code 214450) has filed an annual report on March 19, 2026 with DART. SignalX tracks every new DART disclosure with AI-powered English summaries of business overview, risk factors, and management discussion.

When did Pharmaresearch file its most recent annual report?

Pharmaresearch filed its most recent annual report on March 19, 2026. The annual report includes audited financial statements, business overview, risk factors, and management discussion (MD&A), all available on SignalX with AI-generated English summaries and KIFRS financial data.

What is Pharmaresearch's KRX stock code?

Pharmaresearch's KRX stock code is 214450. The 6-digit stock code is the KRX standard identifier for every listed security. You can use stock code 214450 to look up all Pharmaresearch disclosures on DART, or browse them here on SignalX with AI-powered English analysis.

How often does Pharmaresearch file with DART?

Korean listed companies file an annual report once per year (typically within 90 days of fiscal year-end), a half-year report once mid-year, and quarterly reports for Q1 and Q3 — three regular periodic disclosures plus the annual. Material event reports are filed as needed when corporate events occur. SignalX monitors DART daily.

What is the difference between annual, half-year, and quarterly reports in Korea?

An annual report is a comprehensive filing with audited financials, business overview, and risk factors — analogous to the US 10-K. A half-year (interim) report covers H1 results. Quarterly reports cover Q1 or Q3 — analogous to the US 10-Q but Korea publishes only two quarterly reports per year (with the half-year report covering Q2). SignalX provides AI-generated English summaries for all three filing types for Pharmaresearch.

Where can I find Pharmaresearch financial data and KIFRS metrics?

SignalX extracts KIFRS consolidated financial data from Pharmaresearch annual reports, including revenue, gross profit, operating income, net income, total assets, stockholders' equity, EPS (basic/diluted), operating cash flow, and capital expenditure — all in KRW. Multi-year financial trends are displayed in the Financial Summary table above.